ARC-520

tonychant

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress™ 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
Collectively, these presentations demonstrate several important findings from Arrowhead's clinical and nonclinical studies of ARC-520, including the following:
Š ARC-520 and entecavir produced rapid HBV DNA suppression with all hepatitis B e-antigen (HBeAg) positive, treatment naïve patients achieving serum HBV DNA reductions of up to 5.5 log (99.9997%), and all HBeAg negative,
treatment naïve patients achieving reductions that put them below the limit of quantitation Š ARC-520 effectively inhibited HBV cccDNA-derived mRNA with observed viral protein reduction in HBV patients of up to 2.0 log (99%) after a single dose Š Based on HBsAg epitope profile analysis, poster authors and Arrowhead collaborators had previously identified a predictive hepatitis B surface-antigen (HBsAg) Clearance Profile associated with HBsAg clearance in antiviral therapy cohorts
Š There was a significant association between the development of an HBsAg Clearance Profile and ARC-520 therapy in HBV patients Š Complexed HBsAg antibodies (anti-HBs) were developed and detected in HBV patients treated with ARC-520, which may represent a recovery of the immune system responseŠ After monthly administration of 6-11 doses of ARC-520 in chimpanzees chronically infected with HBV, the ARC-520 target site sequences remained virtually unchanged, indicating that no drug resistance developed during the treatment period

tonychant

加利福尼亚州帕萨迪纳 - （BUSINESS WIRE） - 箭头制药公司（纳斯达克股票代码：ARWR）今天宣布，三个介绍正在对ARC-520发，其研究性药物治疗慢性乙型肝炎病毒感染的治疗，在国际肝病会议™2016（ILC 2016），在西班牙巴塞罗那，2016年4月13-17日。
总的来说，这些演示展示从箭头的ARC-520的临床和非临床研究，主要包括以下几个重要发现：
?? ARC-520和恩替卡韦生产快速HBV DNA抑制所有乙肝e抗原（HBeAg）阳性阳性，高达5.5日志（99.9997％），以及所有HBeAg阴性的初次接受治疗的患者达到血清HBV DNA减少，
初次接受治疗的患者达到了把它们低于定量限值降低？ ARC-520有效地抑制HBV的cccDNA衍生的mRNA与单一剂量后观察到的病毒蛋白质的减少最多2.0日志（99％）的HBV的患者??基于表位乙肝表面抗原谱分析，海报作者和合作者慈姑此前确定的预测乙肝表面抗原（HBsAg）的间隙轮廓与抗病毒治疗的同伙HBsAg清除相关
??有一个的HBsAg减价资料的发展和ARC-520治疗的HBV患者之间的一个显著关联
??络合的HBsAg抗体（抗-HBs）进行了开发和在与ARC-520治疗的HBV患者检测，其可代表免疫系统应答的恢复
??在慢性感染HBV的黑猩猩6-11剂量ARC-520的每月给药后，对ARC-520靶位点序列几乎没有变化，这表明无耐药性治疗期间开发的

愚人

好！

fs2002

期待ARC－520